ctDNA-guided rechallenge with cetuximab plus irinotecan shows activity in RAS/BRAF wild-type mCRC

▸ TREATMENT

A Phase II trial enrolled patients with RAS/BRAF wild-type metastatic colorectal cancer who had progressed on prior cetuximab-based therapy, using circulating tumor DNA testing to select patients for rechallenge with cetuximab plus irinotecan. (Clinical and Translational Medicine)